Key Findings
- Analysis of 13,731 endometrial cancers profiled by Caris showed that ADC target expression varied by molecular subtype, supporting subtype-specific biomarker evaluation for future ADC development.
- This study highlights how genomic, transcriptomic, immune, and biomarker profiling can refine gynecologic cancer subgroups, inform therapeutic development, and reveal clinically relevant differences in treatment response and outcomes.